CSPC Pharmaceutical Group Limited



PE Ratio
Market Cap
52 Week Range
$1.00 - $2.05
Operating Margin
Dividend & Yield
$0.11 (9.73%)
Rev. per Share

About CSPC Pharmaceutical Group Limited

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke and memory and mental impairment; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Xuanning for hypertension; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; Enxi to treat adult idiopathic Parkinson's disease; Keaili for breast cancer; Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; and Encun to prevent atherosclerotic thrombosis events. It also offers Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; Gaoshunsong for arthritis, rheumatoid, and various pain; Debixin for various ulcer; and Qimaite for acute and chronic pains. In addition, the company provides antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and researches and develops various products with focus on the therapeutic areas of oncology, autoimmunity, psychiatry and neurology, digestion and metabolism, cardio-cerebrovascular system, and anti-infection. Further, it offers healthcare services and sells pharmaceutical equipment. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.


News about CSPC Pharmaceutical Group Limited

CSPC Pharmaceutical Group Limited

About kinfo
Kinfo is an app for DIY traders and investors. Kinfo tracks your trading performance and lets you compare measurable performance metrics against other traders. Kinfo works for day trading, swing trading and longer holding periods. By tracking portfolio performance kinfo allows traders to learn, find inspiration and gain confidence.
Get Social
Download the App

Trading involves significant risk of loss. It is not suitable for all investors and you should make sure you understand the risks involved, seeking independent advice if necessary.

Never risk more than you are willing to lose. Trading futures and other derivatives may cause losses that exceed deposits.

Hypothetical performance results have inherent limitations, some of which are described below. Kinfo makes no representation that any trading account will or is likely to achieve profits or losses like those shown. There are often sharp differences between hypothetical trading performance results and the actual results subsequently achieved by any trading program. Past results of advertised trading systems, profit statements, charts or any other representations are not indicative of future performance.

Kinfo is an educational site and is not a financial adviser or broker. All stocks, ETFs, commodities, Indices, Forex, Bonds, and other securities mentioned in our courses are for educational and illustrative purposes only. If you need professional investment advice, please consult a registered investment adviser. Futures and Options carry risk and may not be suitable for everyone.

Kinfo demonstrates specific advanced approaches (or methods). Any mention of Return of Investment percentages is only indicative of the potential of the strategy or the system and is not meant to signify any guaranteed returns.

Success in trading involves a range of human factors like decision making skills, adjustment skills, emotional control, and risk management and other psychological and behavioral parameters, all of which are completely in the hands of the individual. Trading involves significant risk of loss. It is not suitable for all investors.

Charts on kinfo provided by TradingView